667 completed, 262 terminated, 211 recruiting, 141 unknown. 1539 Phase 2, 375 Phase 1, 34 Phase 3.
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer TTP-ICG NIR fluorescent diagnostic agent - NMIBC | Phase 1 / Phase 2 | Not yet recruiting | Yunnan Cancer Hospital | 30 | 2026-10-30 | 2026-09-24 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Enfortumab vedotin, Pembrolizumab, Cisplatin - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 70 | 2026-10-16 | 2026-11-02 |
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT Toripalimab (JS001 ), Gemcitabine (GEM) - Non Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Tianjin First Central Hospital | 54 | 2026-10-01 | 2026-09-08 |
Showing 20 of 1539. Sign in to see all of them.
Carcinoma, Renal Cell (816) · Urinary Bladder Neoplasms (522) · Kidney Neoplasms (340) · Melanoma (145) · Carcinoma, Non-Small-Cell Lung (132) · Carcinoma, Transitional Cell (131) · Neoplasm Metastasis (131) · Neoplasms (97) · Non-Muscle Invasive Bladder Neoplasms (94) · Ovarian Neoplasms (82) · Sarcoma (79) · Breast Neoplasms (77) · Colorectal Neoplasms (75) · Wilms Tumor (67) · Stomach Neoplasms (64)
Female Urogenital Diseases (1538) · Female Urogenital Diseases and Pregnancy Complications (1538) · Urogenital Diseases (1538) · Male Urogenital Diseases (1537) · Urologic Diseases (1532) · Neoplasms by Site (1531) · Urogenital Neoplasms (1522) · Neoplasms (1442) · Neoplasms by Histologic Type (1135) · Neoplasms, Glandular and Epithelial (1093) · Carcinoma (1028) · Kidney Diseases (977) · Adenocarcinoma (840) · Kidney Neoplasms (639)
Gemcitabine (144) · pembrolizumab (123) · Nivolumab (112) · Sunitinib (87) · Cisplatin (83) · Bevacizumab (58) · Sorafenib (51) · Axitinib (50) · Magnetic Resonance Spectroscopy (49) · Everolimus (46) · Ipilimumab (46) · Specimen Handling (43) · aldesleukin (41) · cabozantinib (41) · Carboplatin (38)
National Cancer Institute (NCI) (136) · M.D. Anderson Cancer Center (55) · Memorial Sloan Kettering Cancer Center (48) · Merck Sharp & Dohme LLC (19) · Pfizer (18) · Hoffmann-La Roche (15) · Case Comprehensive Cancer Center (13) · Eli Lilly and Company (13) · Fred Hutchinson Cancer Center (13) · University of Michigan Rogel Cancer Center (13) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (12) · Fudan University (12) · Novartis Pharmaceuticals (12) · SWOG Cancer Research Network (12) · AstraZeneca (11)
United States (954) · China (151) · Canada (139) · France (135) · United Kingdom (132) · Spain (123) · Italy (111) · Australia (89) · Germany (86) · South Korea (76) · Netherlands (68) · Belgium (52) · Poland (42) · Japan (38) · Russia (32)
Eric Jonasch, MD (12) · Giuseppe Procopio, MD (8) · Dr. Sandy Srinivas (6) · Robert J Amato, DO (6) · Robert J. Motzer, MD (6) · Walter M. Stadler, MD, FACP (6) · Dean Bajorin, MD (5)
PMID 37146227, PMID 31401903, PMID 27238653, PMID 28410911, PMID 25577718, PMID 19097774, PMID 32499241, PMID 17340590, PMID 19179301, PMID 21403127, PMID 22430088, PMID 22980441, PMID 23964934, PMID 25366678, PMID 25428503, PMID 25532471, PMID 26706103, PMID 26952546, PMID 27324428, PMID 29489427, PMID 31838007, PMID 33604999, PMID 34051177, PMID 34125951, PMID 35420628, PMID 36848607, PMID 37496366, PMID 37699333, PMID 38740030, PMID 38953850, PMID 39462179, PMID 40086048, PMID 41044356, PMID 41074972, PMID 41969229, PMID 10519404, PMID 10673991, PMID 10751849, PMID 10984562, PMID 11224527, PMID 11282341, PMID 11698646, PMID 11743264, PMID 12091876, PMID 12118019, PMID 12419754, PMID 12448661, PMID 12538684, PMID 12586807, PMID 12767086
2023 (20), U10CA180886 (17), 2017 (14), 2016 (13), U10CA032102 (13), 2015 (11), 2019 (10), 2018 (9), P30CA015704 (9), P30CA033572 (9), P30CA043703 (9), U10CA031946 (8), 2008 (7), 2025 (7), P30CA016672 (7)